All Stories

MaaT Pharma : Pioneering microbiome-driven therapy as new pillar in oncology

CEO Hervé Affagard discusses MaaT Pharma's new approach to microbiome-driven therapies and impressive Phase 3 results in treating acute Graft-versus Host disease.

Feb 10, 2025 - 16:31
 0
MaaT Pharma : Pioneering microbiome-driven therapy as new pillar in oncology
CEO Hervé Affagard discusses MaaT Pharma's new approach to microbiome-driven therapies and impressive Phase 3 results in treating acute Graft-versus Host disease.
Read More

Tags:

Previous Article

Walgreens: Bridging the gap between patient and medication

Next Article

Is it time for HLS to embrace industry-specific cloud?

Related Posts

Moderna shoulders $238M contract manufacturing cancellation charge in Q4

Moderna shoulders $238M contract manufacturing cancella...

Feb 14, 2025  0

Don't call it a comeback: Pfizer returns to Super Bowl with ad pledging to 'knock out' cancer

Don't call it a comeback: Pfizer returns to Super Bowl ...

Feb 9, 2025  0

Amid Merck supply squeeze, ImmunityBio and Serum Institute snag FDA blessing for BCG expanded access program

Amid Merck supply squeeze, ImmunityBio and Serum Instit...

Feb 19, 2025  0